（以下内容从东吴证券《医药生物行业跟踪周报：医疗器械出海重要性日益凸显，关注新产业、三诺生物、迈瑞医疗等》研报附件原文摘录） 投资要点 本周、年初至今（2024年9月20日）医药指数涨幅分别为-0.79%、-27.56%，相对沪深300的超额收益分别为-2.11%、-20.86%；本周医药商业（+1.83%）、医疗服务（+1.12%）及中药（+0.84%）等股价跌幅较小，化学制药（-2.34%）、 ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC. RAHWAY, N.J., September 18, 2024--Merck ...

据新华社9月17日报道，一个国际研究团队近日在英国学术期刊《柳叶刀》上发表论文说，2025年至2050年间，全球预计将有超过3900万人死于抗生素耐药性。研究人员17日接受新华社记者采访时指出，抗生素耐药性已成为全球公共卫生的重大挑战，必须采取果断行动应对这一威胁。

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

In the trial, most interstitial lung disease events were observed to be low grade, with two grade 5 ILD events being reported ...

The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC patients who received prior EGFR ...